Proliferation of early human myeloid precursors induced by interleukin-1 and recombinant soluble CD23.
Low affinity Fc epsilon receptors (Fc epsilon RII/CD23) or their soluble fragments have various biologic effects on B- and T-cell lineages. In this study, we have assessed the effect of recombinant soluble CD23 (rsCD23) on the proliferation of human bone marrow (BM)-derived myeloid precursors with or without recombinant interleukin-1 (rIL-1) addition. Non-adherent CD2- or CD34+ BM cell subsets were used as target cells. Our results show that rsCD23 in synergy with rIL-1 displays an interleukin-3-like activity as it promotes the proliferation of multipotential marrow precursors. This effect was abolished by anti-CD23 addition to these cultures, but was not affected by anti-IL-3 monoclonal antibody. Furthermore, sequential study indicates that rIL-1 induces bone marrow cell responsiveness to rsCD23.
Mossalayi
M D
MD
Cellular Immunology Department, CNRS URA186, La Pitié-Salpêtrière Hospital, Paris, France.
Arock
M
M
Bertho
J M
JM
Blanc
C
C
Dalloul
A H
AH
Hofstetter
H
H
Sarfati
M
M
Delespesse
G
G
Debré
P
P
D000944:Antigens, Differentiation, B-Lymphocyte / Q000494:pharmacology*; D001853:Bone Marrow / Q000187:drug effects; D001854:Bone Marrow Cells; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D006801:Humans; D007375:Interleukin-1 / Q000494:pharmacology*; D011961:Receptors, Fc / Q000494:pharmacology*; D017455:Receptors, IgE; D011994:Recombinant Proteins / Q000494:pharmacology*; D012995:Solubility; D013234:Stem Cells / Q000166:cytology* / Q000187:drug effects
D000944:Antigens, Differentiation, B-Lymphocyte; D007375:Interleukin-1; D011961:Receptors, Fc; D017455:Receptors, IgE; D011994:Recombinant Proteins